Systemic Treatment After Locoregional Recurrence in Breast Cancer: A Review

키워드

참고문헌 (66)

1. Fisher B, "Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer", N Engl J Med, 347, pp.1233~1241 (2002)
2. Veronesi U, "Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer", N Engl J Med, 347, pp.1227~1232 (2002)
3. Blichert-Toft M, "Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer : 20-year follow-up of the Danish randomized DBCG-82TM protocol", Acta Oncol, 47, pp.672~681 (2008)
4. Kuerer HM, "Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence : the potential role of partial breast irradiation", Cancer, 100, pp.2269~2280 (2004)
5. Schuck A, "Radiotherapy in the treatment of locoregional relapses of breast cancer", Br J Radiol, 75, pp.663~669 (2002)
6. Hannoun-Levi JM, "Local treatment options for ipsilateral breast tumour recurrence", Cancer Treat Rev, 39, pp.737~741 (2013)
7. Wapnir IL, "Poor prognosis after second locoregional recurrences in the CALOR trial", Ann Surg Oncol, 24, pp.398~406 (2017)
8. Fisher B, "Significance of ipsilateral breast tumour recurrence after lumpectomy", Lancet, 338, pp.327~331 (1991)
9. Wapnir IL, "Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials", J Clin Oncol, 24, pp.2028~2037 (2006)
10. Nielsen HM, "Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials", Radiother Oncol, 79, pp.147~155 (2006)
11. Anderson SJ, "Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer", J Clin Oncol, 27, pp.2466~2473 (2009)
12. Botteri E, "Unavoidable mastectomy for ipsilateral breast tumour recurrence after conservative surgery : patient outcome", Ann Oncol, 20, pp.1008~1012 (2009)
13. Rauschecker H, "Systemic therapy for treating locoregional recurrence in women with breast cancer", Cochrane Database Syst Rev, 2001, pp.CD002195~ (2001)
14. Buchholz TA, "Multidisciplinary management of locoregional recurrent breast cancer", J Clin Oncol, 38, pp.2321~2328 (2020)
15. Aberizk WJ, "The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy", Cancer, 58, pp.1214~1218 (1986)
16. "Schweiz Med Wochenschr", 1988, 1976~1981
17. Schwaibold F, "The results of radiation therapy for isolated local regional recurrence after mastectomy", Int J Radiat Oncol Biol Phys, 21, pp.299~310 (1991)
18. Willner J, "Locoregional recurrence of breast cancer following mastectomy : always a fatal event? Results of univariate and multivariate analysis", Int J Radiat Oncol Biol Phys, 37, pp.853~863 (1997)
19. Kamby C, "Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up", Breast Cancer Res Treat, 45, pp.181~192 (1997)
20. Stotter A, "Survival following locoregional recurrence after breast conservation therapy for cancer", Ann Surg, 212, pp.166~172 (1990)
21. Fowble B, "Breast recurrence following conservative surgery and radiation : patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment", Int J Radiat Oncol Biol Phys, 19, pp.833~842 (1990)
22. Haffty BG, "Prognosis following local recurrence in the conservatively treated breast cancer patient", Int J Radiat Oncol Biol Phys, 21, pp.293~298 (1991)
23. Halverson KJ, "Survival following locoregional recurrence of breast cancer : univariate and multivariate analysis", Int J Radiat Oncol Biol Phys, 23, pp.285~291 (1992)
24. Abner AL, "Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer", J Clin Oncol, 11, pp.44~48 (1993)
25. Cajucom CC, "Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy", Cancer, 71, pp.1774~1779 (1993)
26. Leborgne F, "Breast conservation treatment of early stage breast cancer : patterns of failure", Int J Radiat Oncol Biol Phys, 31, pp.765~775 (1995)
27. Haffty BG, "Ipsilateral breast tumor recurrence as a predictor of distant disease : implications for systemic therapy at the time of local relapse", J Clin Oncol, 14, pp.52~57 (1996)
28. Dalberg K, "Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer", Breast Cancer Res Treat, 49, pp.69~78 (1998)
29. Doyle T, "Long-term results of local recurrence after breast conservation treatment for invasive breast cancer", Int J Radiat Oncol Biol Phys, 51, pp.74~80 (2001)
30. Waeber M, "Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence : definitive results of a phase III randomized trial(SAKK 23", 82)comparing tamoxifen with observation, 2003, pp.14, 1215~1221
31. Voogd AC, "Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer", Eur J Cancer, 41, pp.2637~2644 (2005)
32. Lee YJ, "Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer", Breast Cancer Res Treat, 179, pp.315~324 (2020)
33. Murata T, "A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer", Breast Cancer Res Treat, 199, pp.57~66 (2023)
34. Wapnir IL, "A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer : IBCSG 27-02, BIG 1-02, and NSABP B-37", Clin Breast Cancer, 8, pp.287~292 (2008)
35. Yi M, "Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning", Ann Surg, 253, pp.572~579 (2011)
36. Smith TE, "True recurrence vs. new primary ipsilateral breast tumor relapse : an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management", Int J Radiat Oncol Biol Phys, 48, pp.1281~1289 (2000)
37. Kuo SH, "Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence", Int J Radiat Oncol Biol Phys, 72, pp.1456~1464 (2008)
38. Montagna E, "Breast cancer subtypes and outcome after local and regional relapse", Ann Oncol, 23, pp.324~331 (2012)
39. Aebi S, "Chemotherapy for isolated locoregional recurrence of breast cancer(CALOR) : a randomised trial", Lancet Oncol, 15, pp.156~163 (2014)
40. Wapnir IL, "Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer : final analysis of the CALOR trial", J Clin Oncol, 36, pp.1073~1079 (2018)
41. Balic M, "St. Gallen", Vienna 2023 : optimization of treatment for patients with primary breast cancer-a brief summary of the consensus discussion, 2023, pp.18, 213~222
42. Reinhardt K, "PIK3CA-mutations in breast cancer", Breast Cancer Res Treat, 196, pp.483~493 (2022)
43. Ferrando L, "ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer(HR+ HER2-BC)", PLoS Genet, 19, pp.e1010563~ (2023)
44. Gnant M, "Adjuvant palbociclib for early breast cancer : the PALLAS trial results(ABCSG-42", AFT-05, J Clin Oncol, pp.2022, 40[DOI]
45. Johnston SRD, "Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer(monarchE)", J Clin Oncol, 38, pp.3987~3998 (2020)
46. Morgan JL, "The MARECA(national study of management of breast cancer locoregional recurrence and oncological outcomes)study : national practice questionnaire of United Kingdom multi-disciplinary decision making", Eur J Surg Oncol, 48, pp.1510~1519 (2022)
47. Finn RS, "Palbociclib and letrozole in advanced breast cancer", N Engl J Med, 375, pp.1925~1936 (2016)
48. Hortobagyi GN, "Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer", Ann Oncol, 29, pp.1541~1547 (2018)
49. Goetz MP, "MONARCH 3 : abemaciclib as initial therapy for advanced breast cancer", J Clin Oncol, 35, pp.3638~3646 (2017)
50. Tripathy D, "Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer(MONALEESA-7) : a randomised phase 3 trial", Lancet Oncol, 19, pp.904~915 (2018)
51. Slamon DJ, "Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer : MONALEESA-3", J Clin Oncol, 36, pp.2465~2472 (2018)
52. Slamon DJ, "Overall survival with ribociclib plus fulvestrant in advanced breast cancer", N Engl J Med, 382, pp.514~524 (2020)
53. Turner NC, "Palbociclib in hormone-receptor-positive advanced breast cancer", N Engl J Med, 373, pp.209~219 (2015)
54. Cristofanilli M, "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy(PALOMA-3) : final analysis of the multicentre, double-blind, phase 3 randomised controlled trial", Lancet Oncol, 17, pp.425~439 (2016)
55. Sledge GW, Jr, "MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+", HER2- advanced breast cancer who had progressed while receiving endocrine therapy, 2017, pp.35, 2875~2884
56. Sledge GW, Jr., "The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial", JAMA Oncol, 6, pp.116~124 (2020)
57. Swain SM, "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA) : end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study", Lancet Oncol, 21, pp.519~530 (2020)
58. Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
59. Robson M, "Olaparib for metastatic breast cancer in patients with a germline BRCA mutation", N Engl J Med, 377, pp.523~533 (2017)
60. Litton JK, "Talazoparib in patients with advanced breast cancer and a germline BRCA mutation", N Engl J Med, 379, pp.753~763 (2018)
61. Tutt A, "Carboplatin in BRCA1", 2-mutated and triple-negative breast cancer BRCAness subgroups : the TNT Trial, 2018, pp.24, 628~637
62. Drilon A, "Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children", N Engl J Med, 378, pp.731~739 (2018)
63. Drilon A, "TRK inhibitors in TRK fusion-positive cancers", Ann Oncol, 30(suppl 8), pp.viii23~viii30 (2019)
64. Adams S, "Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer : cohort B of the phase II KEYNOTE-086 study", Ann Oncol, 30, pp.405~411 (2019)
65. Pedersen AN, "Supraclavicular recurrence after early breast cancer : a curable condition?", Breast Cancer Res Treat, 125, pp.815~822 (2011)
66. Brito RA, "Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases : the University of Texas M. D. Anderson Cancer Center experience", J Clin Oncol, 19, pp.628~633 (2001)

관련 논문AI추천